Targeting solid tumours with potassium channel activators. A return to fundamentals?

Area of Science:

• Pharmacology
• Oncology
• Radiotherapy

Background:

• Nicotinamide is a radiosensitizer used in accelerated radiotherapy combined with carbogen breathing and nicotinamide (ARCON) therapy.
• Minoxidil, a potassium channel activator, has not been previously explored in radiotherapy.
• Recent pathophysiological insights suggest potential applications for both molecules in solid tumor treatment.

Discussion:

• This study proposes a novel perspective on utilizing nicotinamide and minoxidil for solid tumor targeting.
• Both compounds function as potassium channel activators, a shared pharmacological characteristic.
• The potential of minoxidil in radiotherapy warrants investigation, building upon nicotinamide's established role.

Key Insights:

• Nicotinamide and minoxidil are identified as potassium channel activators with potential anticancer applications.
• The established use of nicotinamide in ARCON therapy provides a basis for exploring its radiosensitizing capabilities.
• Minoxidil represents a novel therapeutic agent to consider within radiation oncology.

Outlook:

• Further preclinical and clinical studies are required to validate the efficacy of nicotinamide and minoxidil in solid tumor treatment.
• Investigating the synergistic effects of these potassium channel activators in combination with radiotherapy could yield significant advancements.
• Exploring the specific mechanisms by which minoxidil might enhance radiotherapy outcomes is a critical next step.